Synergistic effect of folate-mediated targeting and verapamil-mediated P-gp inhibition with paclitaxel -polymer micelles to overcome multi-drug resistance

被引:176
作者
Wang, Feihu [1 ]
Zhang, Dianrui [1 ]
Zhang, Qiang [2 ]
Chen, Yuxuan [1 ]
Zheng, Dandan [1 ]
Hao, Leilei [1 ]
Duan, Cunxian [1 ]
Jia, Lejiao [1 ]
Liu, Guangpu [1 ]
Liu, Yue [1 ]
机构
[1] Shandong Univ, Coll Pharm, Dept Pharmaceut, Jinan 250012, Peoples R China
[2] Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100083, Peoples R China
关键词
Paclitaxel; Polymeric micelles; Targeted delivery; Multidrug resistance; Drug efflux; Verapamil; ANTICANCER DRUGS; INTRACELLULAR DELIVERY; CYTO-TOXICITY; LUNG-CANCER; CELL LINES; TUMOR; GLYCOPROTEIN; NANOPARTICLES; DOXORUBICIN; COPOLYMER;
D O I
10.1016/j.biomaterials.2011.08.041
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Multidrug resistance (MDR) in tumor cells is a significant obstacle for successful cancer chemotherapy. Overexpression of drug efflux transporters such as P-glycoprotein (P-gp) is a key factor contributing to the development of tumor drug resistance. Verapamil (VRP), a P-gp inhibitor, has been reported to be able to reverse completely the resistance caused by P-gp. For optimal synergy, the drug and inhibitor combination may need to be temporally colocalized in the tumor cells. Herein, we investigated the effectiveness of simultaneous and targeted delivery of anticancer drug, paclitaxel (PTX), along with VRP, using DOMC-FA micelles to overcome tumor drug resistance. The floate-functionalized dual agent loaded micelles resulted in the similar cytotoxicity to PTX-loaded micelles/free VRP combination and co-administration of two single-agent loaded micelles, which was higher than that of PTX-loaded micelles. Enhanced therapeutic efficacy of dual agent micelles could be ascribe to increased accumulation of PTX in drug-resistant tumor cells. We suggest that the synergistic effect of folate receptor-mediated internalization and VRP-mediated overcoming MDR could be beneficial in treatment of MDR solid tumors by targeting delivery of micellar PTX into tumor cells. As a result, the difunctional micelle systems is a very promising approach to overcome tumor drug resistance. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:9444 / 9456
页数:13
相关论文
共 40 条
[1]  
Adcock Ian M, 2005, Proc Am Thorac Soc, V2, P313, DOI 10.1513/pats.200504-035SR
[2]   Susceptibility of nanoparticle-encapsulated paclitaxel to P-glycoprotein-mediated drug efflux [J].
Chavanpatil, Mahesh D. ;
Patil, Yogesh ;
Panyam, Jayanth .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 320 (1-2) :150-156
[3]  
DEFFIE AM, 1989, CANCER RES, V49, P58
[4]   Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors [J].
Ho, Emmanuel A. ;
Soo, Patrick Lim ;
Allen, Christine ;
Piquette-Miller, Micheline .
JOURNAL OF CONTROLLED RELEASE, 2007, 117 (01) :20-27
[5]   MODULATION BY VERAPAMIL OF VINCRISTINE PHARMACOKINETICS AND TOXICITY IN MICE BEARING HUMAN-TUMOR XENOGRAFTS [J].
HORTON, JK ;
THIMMAIAH, KN ;
HOUGHTON, JA ;
HOROWITZ, ME ;
HOUGHTON, PJ .
BIOCHEMICAL PHARMACOLOGY, 1989, 38 (11) :1727-1736
[6]  
Huang M, 1999, CANCER LETT, V135, P97
[7]   Pluronic® block copolymers for overcoming drug resistance in cancer [J].
Kabanov, AV ;
Batrakova, EV ;
Alakhov, VY .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :759-779
[8]   In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy [J].
Kim, SC ;
Kim, DW ;
Shim, YH ;
Bang, JS ;
Oh, HS ;
Kim, SW ;
Seo, MH .
JOURNAL OF CONTROLLED RELEASE, 2001, 72 (1-3) :191-202
[9]   The role of Bcl-2 family members in tumorigenesis [J].
Kirkin, V ;
Joos, S ;
Zörnig, M .
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH, 2004, 1644 (2-3) :229-249
[10]   Multidrug resistance (MDR) in cancer - Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs [J].
Krishna, R ;
Mayer, LD .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 (04) :265-283